[Therapy of acute leukemia. Results of the Swiss study group for clinical cancer research (SAKK)].
D000367:Age Factors; D001856:Bone Marrow Examination; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D009607:Nitrosourea Compounds; D003561:Cytarabine; D014750:Vincristine; D015122:Mercaptopurine; D013866:Thioguanine; D011241:Prednisone; D006918:Hydroxyurea; D003630:Daunorubicin
Die Therapie der akuten Leukämie. Ergebnisse der Schweizerischen Arbeitsgemeinschaft für klinische Krebsforschung (SAKK.